Liquid biopsy startup Freenome Inc., of South San Francisco, reeled in $160 million in series B financing that was led by RA Capital Management and Polaris Partners. The funds are earmarked to advance Freenome's multiomics blood testing platform for early cancer detection and to grow its laboratory and software capabilities. Founded in 2014, Freenome applies machine learning technology to fragments of DNA and RNA, known as freenomes, that are circulating in the blood after being sloughed off by dying cells in the body. The aim is monitor immune system, metabolic and other changes in the body's reaction to malignant cells. Read More
